



CareFirst Sales Flash

For Distribution to Brokers/General Producers/Full-Service Producers Only
(Not intended for distribution to Groups and Members)



Date: November 2, 2017
Market: All

2018 Formulary Lists and Disruption Information

Together with CVS Caremark, our pharmacy benefit manager, we continuously monitor the marketplace and adjust our formularies to address rising drug trends. With these adjustments, drugs may move to a different tier or may no longer be covered. In addition, there may be changes to the prescription guideline requirements, including prior authorization, step therapy and quantity limits. Members who are negatively impacted by the formulary changes will be notified by letter about covered alternatives.

All Formulary lists for 2018 are now available on www.carefirst.com/rx (ACA Small Group/Consumer Direct and 51+ Fully Insured) and www.carefirst.com/rxgroup (Self Insured).

New and improved webpages have been developed for both Risk and ASO to differentiate the 2017 and 2018 formularies and to provide a more seamless experience for our members. Members should continue to use their current 2017 formularies (i.e., Formulary 2) until they renew in 2018.

Segment	Formulary Lists	Tier Structure
Consumer Direct and 2-50 Risk	Exchange Formulary	5 Tier
51+ Risk	Formulary 3	5 Tier
ASO	Formulary 1	3 Tier
ASO	Formulary 1	4 Tier
ASO	Formulary 1	5 Tier
ASO	Formulary 2	3 Tier
ASO	Formulary 2	4 Tier
ASO	Formulary 2	5 Tier
ASO	Formulary 3	5 Tier
FEHBP	Formulary 2	5 Tier
Grandfathered Risk	Formulary 2	3 Tier
Grandfathered Risk	Formulary 2	4 Tier
Other Lists		
	Preferred Drug List – Formulary 1	
	Preferred Drug List – Formulary 2	
	Preferred Drug List – Formulary 3	
	Preventive Drug List*	
	Prescription Guidelines	
	Specialty Drug List	
	Formulary Drug Removals for Formulary 2	
	Formulary Drug Removals for Formulary 3	
	Drugs Requiring Prior Authorization for Medical Necessity (2017 ACA Formulary 2)	
	Drugs Requiring Prior Authorization for Medical Necessity (2017 51+ Risk Non-ACA Formulary 2 and Grandfathered)	

*Low-moderate dose generic statins will be available at no cost for eligible members (age 40-75) effective November 1, 2017.



CareFirst Sales Flash

For Distribution to Brokers/General Producers/Full-Service Producers Only
(Not intended for distribution to Groups and Members)

Disruption Information: 51+ Group Business

The following formulary changes are effective January 1, 2018:

- For Formulary 1, there are no drug exclusions.
- For Formulary 2, the drug exclusions resulted in the removal of 17 products in 10 drug classes with 99.76 percent of members being able to stay on their current therapy. Drugs were removed only when clinically-appropriate, lower-cost (often generic) alternatives are available.
- For Risk members moving from Formulary 2 with prior authorizations to Formulary 3 with exclusions, approximately 8% of members will be negatively impacted.

Segment	2017 Formulary	2018 Formulary	Disruption
Non-Risk	Formulary 1 (No Exclusions)	Formulary 1 (No Exclusions)	N/A
Non-Risk	Formulary 2 with Exclusions Approximately 130 products excluded	Formulary 2 with Exclusions Approximately 159 products excluded	0.25%
Non-Risk	Formulary 3 with Exclusions Approximately 200 products excluded	Formulary 3 with Exclusions Approximately 258 products excluded	N/A—No current groups
Risk	Formulary 2 with Prior Authorizations Approximately 130 products with medically necessary prior authorizations	Formulary 3 with Exclusions Approximately 258 products excluded	8%

Note: Pen needles, syringes and test strips are additional to the total number of products that are excluded or require a prior authorization for each of the formularies.



CareFirst Sales Flash

For Distribution to Brokers/General Producers/Full-Service Producers Only
(Not intended for distribution to Groups and Members)

Disruption Information: ACA Business

Impact	Utilizer Count	Utilizer %	Rx Count	Rx %
None	350,498	75.30%	2,802,624	91.20%
Positive	52,480	11.30%	112,931	3.70%
Negative	62,405	13.40%	157,147	5.10%
Total	465,383	100.00%	3,072,702	100.00%

Summary of the percentage of utilizers on the member disruption chart for Exchange members:

- Most members (approximately 75%) will not be impacted.
- Approximately 11% of members will be positively impacted because they are taking a drug that is moving to a lower cost tier.
- Approximately 13% of members will experience a negative disruption because their drug is being excluded, moving to a higher cost tier or has added utilization management criteria.
- A member can fall into both the negative and positive impact buckets so the Total row does not reflect the total eligible.

Summary of the percentage of impacted drugs on the member disruption chart:

- Over 91% of the drugs will not be impacted.
- Nearly 4% of the drugs will be positively impacted.
- Approximately 5% of the drugs will be negatively impacted.

Attached is an Excel spreadsheet that lists the top 25 negatively impacted drugs for ACA disruption which cover about 40% of the negative impacts. The table includes the drug name, drug class, change type (which negative action occurred with the drug), formulary alternatives, percentage of impacted members and the number of impacted drugs.

Should you have any questions, please contact your broker sales representative.

C. Shekar Subramaniam
Vice President, Sales
Small Medium SBU

CareFirst Exchange ACA Disruption by Drug 2018

Experience period: 1/1/2017-08/31/2017

Negative Impact Only

Small Group and Consumer Direct ACA Disruption

Impact	Utilizer count	Utilizer %	Rx count	Rx %
Negative	62,405	13.40%	157,147	5.10%
Positive	52,480	11.30%	112,931	3.70%
None	350,498	75.30%	2,802,624	91.20%
Total	465,383	100.00%	3,072,702	100.00%

Top 25 Negative Impact Drugs

Rank	Drug Name	Drug Class Name	Change Type	Formulary Alternatives	Impacted Mbr Cnt Class %	Impacted Rx Cnt Class Rx %	Impacted Mbr Cnt	Impacted Rx Cnt
1	SUPREP BOWEL PREP KIT	LAXATIVE COMBINATIONS	Neg. Tier Change	GAVILYTE-H KIT, PEG-3350, PREPOPIK PAK	62.31%	61.48%	5579	5649
2	GUAIFENESIN/CODEINE	COUGH/COLD/ALLERGY COMBINATIONS	Some Products Excluded	CHERATUSSIN AC	14.42%	12.89%	2168	2288
3	FLOVENT HFA	STEROID INHALANTS	Exclusion	Asmanex, QVAR	37.68%	33.62%	2015	3613
4	LYRICA	ANTICONVULSANTS - MISC.	Neg. Tier Change	gabapentin	9.77%	8.34%	1958	6418
5	DEXILANT	PROTON PUMP INHIBITORS	Exclusion	esomeprazole, omeprazole, rabeprazole, pantoprazole	6.62%	7.08%	1746	4721
6	HYDROCODONE POLISTIREX/CH	COUGH/COLD/ALLERGY COMBINATIONS	Some Products Excluded	Vituz	10.41%	10.79%	1566	1914
7	BYSTOLIC	BETA BLOCKERS CARDIO-SELECTIVE	Neg. Tier Change	acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol er, nadolol, propranolol, timolol	7.64%	8.04%	1401	4109
8	EPIDUO FORTE	ACNE PRODUCTS	Neg. Tier Change	adapalene-benzoyl peroxide (generic for Epiduo)	10.36%	6.60%	1401	1801
9	ACZONE	ACNE PRODUCTS	Exclusion	Adapalene, benzoyl peroxide, clindamycin, erythromycin, tretinoin	9.55%	6.35%	1291	1731
10	CODEINE/GUAIFENESIN	COUGH/COLD/ALLERGY COMBINATIONS	Some Products Excluded	CHERATUSSIN AC	8.43%	7.73%	1268	1372
11	MINASTRIN 24 FE	COMBINATION CONTRACEPTIVES - ORAL	Exclusion	norethin acet & estrad-fe, MIBELAS 24 CHW FE	3.36%	1.84%	1193	1915
12	DULERA	SYMPATHOMIMETICS	Exclusion	Advair HFA, Symbicort, Breo Ellipta	3.92%	4.48%	1082	2475
13	PREVIDENT 5000 BOOSTER PL	DENTAL PRODUCTS	Exclusion	Sodium Fluoride, FLURA-DROPS, (multiple products on ACA Preventive Services Drug list.)	34.86%	31.57%	1068	1390
14	JARDIANCE	SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS	Neg Tier Change	Invokana, Farxiga	53.33%	50.19%	1048	3101
15	LOTEMAX	OPHTHALMIC STEROIDS	Neg. Tier Change	dexamethasone, fluorometholone, FML Forte, FLAREX	13.39%	13.11%	1023	1375
16	EPIDUO	ACNE PRODUCTS	Exclusion	adapalene-benzoyl peroxide (generic for Epiduo)	6.75%	4.72%	913	1288
17	MOVIPREP	LAXATIVE COMBINATIONS	Neg. Tier Change	GAVILYTE-H KIT, PEG-3350, PREPOPIK PAK	9.69%	9.62%	868	884
18	LIALDA	INFLAMMATORY BOWEL AGENTS	Exclusion	CANASA, APRISO, MESALAMINE, SULFASALAZINE	40.47%	37.62%	781	2481
19	PATADAY	OPHTHALMICS - MISC.	Negative Tier Change	Olopatadine	14.41%	12.99%	758	1159
20	JUBLIA	ANTIFUNGALS - TOPICAL	Neg. Tier Change	Consult Prescriber	4.92%	6.32%	746	1420
21	TRINTELLIX	SEROTONIN MODULATORS	Neg. Tier Change	citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline	8.48%	8.57%	735	2291
22	SOOLANTRA	ROSACEA AGENTS	Exclusion	Finacea 15%, metronidazole, Rosadan	21.74%	14.18%	732	1012
23	AXIRON	ANDROGENS	Exclusion	testosterone gel	34.57%	29.78%	688	2136
24	MUPIROCIN	ANTIBIOTICS - TOPICAL	Some Products Excluded	Ointment Covered (Cream Excluded)	8.07%	7.76%	671	732
25	PRISTIQ	SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)	Exclusion	duloxetine, venlafaxine, venlafaxine ext-rel capsule,	5.64%	3.07%	655	1341